Lohmann's medical sales down again in 1994
This article was originally published in Clinica
German woundcare manufacturer Lohmann has suffered a second year of declining sales in its medical division in 1994. Total revenues, on the other hand, stabilised after a 5% fall in 1993. Lohmann's medical division contributed 53% or DM 200 million ($134 million) to total sales, down 3.8% with declines seen both in Germany and abroad. Lohmann blames price cuts averaging 5.5% which were only partly offset by a 1.7% increase in volume.
You may also be interested in...
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.
Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.